# Jennifer Cygan

> Jennifer Cygan is a seasoned biotech executive and Chief Business Officer at EpiBiologics, where she helps advance a pipeline of novel bispecific antibodies designed to selectively degrade extracellular protein targets in oncology and immunology. With a Ph.D. from Harvard and over two decades of business leadership in biotechnology, she has been a pivotal force at Genentech, Calico Life Sciences (managing a $2.5B AbbVie alliance), and has co-founded and served as CBO for multiple emerging biotech companies including Broadwing Bio, Eikon Therapeutics, GenEdit, and Plexium. Her career sits at the intersection of science and strategy - translating cutting-edge biology into deals, partnerships, and companies that matter.

- **Role:** Chief Business Officer at EpiBiologics
- **Organizations:** EpiBiologics, Broadwing Bio, Eikon Therapeutics, GenEdit, Plexium, Calico Life Sciences, Genentech, University of California, Harvard University
- **Nationality:** American
- **Education:** Ph.D., Harvard University, Bachelor of Sciences, University of Illinois
- **Known for:** Managed Calico Life Sciences' $2.5B strategic alliance with AbbVie, Led stealth phase exit and corporate launch for Eikon Therapeutics as interim CBO and founding leadership team member, Co-founded Broadwing Bio, focused on antibody therapies for vision loss

## Career timeline

- **early career** — Licensing Assistant at Harvard University
- **early career** — Senior Licensing Officer at University of California - technology transfer and licensing
- **mid career** — Director, Business Development at Genencor International Inc - executed strategic out-licensing of clinical stage candidates in oncology and infectious disease
- **mid career** — Associate Director/Head Director, Platform Technologies Business Development at Genentech - strategic technology licensing, collaboration negotiation, Genentech Partnering Group
- **2014-2019** — Head Vice President / Head of Project Team Leader Group at Calico Life Sciences - managed program leadership and Calico's $2.5B strategic alliance with AbbVie
- **2020** — Interim Chief Business Officer at Eikon Therapeutics - led corporate stealth phase exit and launch, established culture and goals as initial leadership team member
- **2020-2022** — Interim Chief Business Officer at GenEdit - led partnering and communications, negotiated therapeutic discovery collaboration with Sarepta
- **2020-2022** — Interim Chief Business Officer at Plexium - established pharma/biotech partnerships, contributed to corporate and pipeline development
- **2021-2023** — Co-Founder and Chief Business Officer at Broadwing Bio - led business development, financing, and program strategy for antibody therapies targeting vision loss
- **2023-present** — Chief Business Officer at EpiBiologics - driving business strategy for targeted protein degradation company backed by GV and JJDC

## Achievements

- Managed Calico Life Sciences' $2.5B strategic alliance with AbbVie
- Led stealth phase exit and corporate launch for Eikon Therapeutics as interim CBO and founding leadership team member
- Co-founded Broadwing Bio, focused on antibody therapies for vision loss
- Negotiated therapeutic discovery collaboration between GenEdit and Sarepta Therapeutics
- Contributed to EpiBiologics' $107M Series B raise (January 2026), co-led by GV and JJDC, bringing total funding to $280M
- Over 20 years of business leadership across biotechnology spanning technology licensing, strategic partnerships, corporate development, and company formation
- Served as interim or founding CBO for four emerging biotech companies simultaneously managing multiple startups

## Latest updates

- **2026-01** — EpiBiologics closes $107M Series B financing co-led by GV (Google Ventures) and Johnson & Johnson Innovation (JJDC), bringing total funding to $280M. Jennifer Cygan is CBO driving business strategy.

## Links

- Website: https://epibiologics.com
- LinkedIn: http://www.linkedin.com/in/jennifer-cygan-baa4626

---

Profile page: https://yespress.io/jennifer-cygan
Published by YesPress — https://yespress.io
Last updated: 2026-05-14